MCL

Toby Eyre | EHA 2018 | Would venetoclax monotherapy be a good option for R/R MCL post-BTK inhibitor therapy?

L: English

23rd Congress of the European Hematology Association, 14-17 June 2018, Stockholm, Sweden

Toby Eyre
Oxford University Hospitals NHS Foundation Trust, Oxford, UK

Interview topic: Would venetoclax monotherapy be a good option for R/R MCL post-BTK inhibitor therapy?

Download this article:

You can now download this article in Adobe PDF® format.

Download as PDF